GLASGOW and BOSTON – September 6, 2018 – Global Clinical Trial Partners (GCTP) has chosen AG Mednet’s Judi as its sole technology provider to deliver its enhanced, rigorous, single-vendor endpoint adjudication services to its clients. GCTP’s independent adjudication offering focuses on management of clinical event committees (CECs). The company provides endpoint adjudication for clinical trials as well as bespoke clinical trial consultancy, with a team of world-renowned clinical trial experts and academics in concert with pharmaceutical industry experts.
With Judi, GCTP will deliver a robust end-to-end, technologically advanced adjudication solution for clients by implementing their expertise in a concise, reproducible and efficient set of workflow methodologies that have been tried and tested in dozens of projects over more than 25 years.
GCTP works collaboratively with clients to determine an approach that best suits their unique needs and handles development of the endpoint process from start to finish. The company manages all aspects of the CEC process from small, single-center to large multinational, multi-center studies. Specific to adjudication, through Judi, GCTP provides:
According to Professor Mark Petrie of GCTP, “AG Mednet’s Judi software is the perfect fit for our bespoke adjudication solutions. The flexibility of their software allows us to easily implement workflow that not only enhances endpoint data quality, but also makes the end-user experience positively enjoyable.”
AG Mednet’s Judi helps advance clinical trials, serving as the first comprehensive electronic endpoint adjudication system to manage workflow and ensure data quality. Judi is an integrated, cloud-based SaaS tool providing a level of flexibility that enables the implementation of the most complex endpoint and adverse event processes, translating into more easily managed projects, fewer queries, higher accountability and increased quality.
“Global Clinical Trial Partners is unique in a number of important ways. Not only have they published pioneering peer-reviewed articles in the most important journals in the world, but they have brought their clinical expertise to a level where sponsors can benefit from their experience. Their customer-centric approach to endpoint adjudication represents a breath of fresh air in the industry. Using Judi as the technology backbone to power their processes is a perfect solution to what is already among the most comprehensive, efficient and accurate approaches to adjudication,” said Abraham Gutman, president and CEO, AG Mednet.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.